Biotech Values

[DewDiligence]

BMY/PFE will present the full Apixaban dataset from the AVERROES study at ESC 8/31/10, as previously promised:

http://finance.yahoo.com/news/BristolMyers-Squibb-and-bw-3220893905.html?x=0&.v=1

Positive top-line data from this study were reported in June (#msg-51176226), which greatly improved the overall commercial prospects for Apixaban. However, the AVERROES study sidestepped the most important segment of the AF market insofar as it compared Apixaban to aspirin in patients unable to tolerate warfarin.

genisi and I predicted that BMY/PFE will defer submitting an NDA for Apixaban in AF until they have the results of the phase-3 study called ARISTOTLE, where Apixaban is compared to warfarin rather than aspirin (#msg-51490977).